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Abstract Platelets interact with bacterial pathogens
through a wide array of cellular and molecular mecha-
nisms. The consequences of this interaction may
signiﬁcantly inﬂuence the balance between infection and
immunity. On the one hand, recent data indicate that cer-
tain bacteria may be capable of exploiting these
interactions to gain a virulence advantage. Indeed, certain
bacterial pathogens appear to have evolved speciﬁc ways in
which to subvert activated platelets. Hence, it is conceiv-
able that some bacterial pathogens exploit platelet
responses. On the other hand, platelets are now known to
possess unambiguous structures and functions of host
defense effector cells. Recent discoveries emphasize criti-
cal features enabling such functions, including expression
of toll-like receptors that detect hallmark signals of bac-
terial infection, an array of microbicidal peptides, as well
as other host defense molecules and functions. These
concepts are consistent with increased risk and severity of
bacterial infection as correlates of clinical abnormalities in
platelet quantity and quality. In these respects, the molec-
ular and cellular roles of platelets in host defense against
bacterial pathogens are explored with attention on advances
in platelet immunobiology.
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Platelets: the other white cells
Invertebrates contain specialized dual-function cells called
hemocytes, which act to maintain hemostasis and defend
against microbial pathogens. These unique cells limit
hemolymph loss upon tissue injury, engage microorgan-
isms introduced by trauma, and coordinate tissue
remodeling and wound repair [1–3]. In higher organisms
including mammals and marsupials, platelets, leukocytes,
and lymphocytes are often viewed as independently
mediating hemostasis, inﬂammation, and immune regula-
tion, respectively [4, 5]. Of course these cells interact with
one another in many ways. Nonetheless, while mammalian
platelets may be best known for their maintenance of
hemostasis, these understudied cells have retained features
of archetypal inﬂammatory cells corresponding to multiple
functions in antimicrobial host defense.
Platelet roles in host defense have been the topic of
recent reviews [1, 6–11]. Thus, the focus of the following
discussion is to provide a framework of understanding the
antimicrobial structures and functions of platelets in
defense against bacterial pathogens.
Platelets are ancient granulocytes
Platelets are small (2–4 lm), discoid cells that originate
from megakaryocyte lineage [12–16]. Platelets have a life
span in the peripheral bloodstream of 5–10 days. These
anucleate cells can perform protein translation using stable
mRNA templates originating from their megakaryocyte
precursors [1, 6–9]. Mature platelets have three distinct
types of cytoplasmic granules. Dense (d) granules are rich
in mediators of vascular tone, such as serotonin, adenosine
diphosphate (ADP), calcium, and phosphate [1, 17]. In
contrast, alpha (a) granules store proteins specialized to
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thrombospondin, vitronectin, laminin, and von Willebrand
factor), coagulation (e.g., plasminogen and a2-plasmin
inhibitor), and endothelial cell repair [e.g., platelet-derived
growth factor (PDGF), permeability factor, and trans-
forming growth factors a and b (TGF-a and TGF-b)] [1, 6–
9]. Platelet a-granules also store an array of microbicidal
proteins (see below). Lysosomal (k) granules contain
enzymes that modulate thrombus dissolution [6–9, 17].
When activated, platelets respond in speciﬁc ways that
emphasize their multiple roles in antimicrobial host
defense, including: (1) activated metabolic status; (2)
metamorphosis from discoid to ameboid shape; (3)
expression of receptors mediating increased adhesivity to
injured or infected tissues; (4) vectored motility toward and
intensiﬁcation at sites of tissue injury or infection; (5)
generation of reactive oxygen species including superox-
ide, peroxide, and hydroxyl radicals; (6) extension of
pseudopodia that interact with microbial pathogens as well
as host cells; (7) cytoskeletal remodeling to facilitate
granule mobilization and organization; and (8) degranula-
tion and processing of preformed granule molecules,
including host defense peptides (see below). The distinct
platelet granules are subject to synchronous or dysyn-
chronous release, depending upon agonist speciﬁcity and
potency. For example, low levels of thrombin or ADP
induce d and a degranulation, whereas k granules are not
secreted until such agonists accumulate to much higher
concentrations [6–9, 18–20].
Platelets serve roles that recapitulate and complement
cell-mediated immune effector cells. In vitro and in
experimental animal models, platelets intensify at sites
enriched in microbial stimuli such as N-formyl-methionyl-
leucyl-phenylalanine (N-f-met-leu-phe) [29] or comple-
ment proteins C3a and C5a [1, 7, 25, 30]. Experiments by
Czapigaa et al. show that platelets express the formyl
peptide receptor (FPR), and surfaces of activated platelets
speciﬁcally ligate N-formyl peptides, followed by calcium
mobilization [31]. Gradient-mediated chemotaxis of
platelets occurs in response to formyl peptides. Notably,
endogenous N-formyl peptides liberated from mitochondria
of necrotic host cells evoke platelet chemotaxis via FPR
recognition; however, cells undergoing apoptotic cell death
do not appear to induce platelet chemotaxis. Such rela-
tionships further implicate archetypal phylogenetic origins
of platelets in host defense against infection.
The concept that platelets contribute to host defense
against infection is substantiated by a line of evidence
relevant to platelet structure and function. For example,
platelets and professional phagocytes such as neutrophils
and monocytes share common surface antigens: the 40-kDa
FccRII receptor [21], FceRI receptor for IgE [22],
C-reactive protein receptor [23], and the thrombospondin
receptor CD36 (platelet GPIV) [24]. Platelets also express
complement CR3 receptor [25], receptors for C3a and C5a
products of complement ﬁxation, and sense and respond to
cytokines such as tumor necrosis factor-a (TNF-a), inter-
leukin-1 (IL-1), and IL-6 in a manner similar to leukocytes
[26, 27]. Clemetson et al. [28] reported that human plate-
lets express functional chemokine receptors, including
CCR1, CCR3, CCR4, and CXCR4.
As discussed below, platelets interact directly and
indirectly with a broad variety of microbial pathogens, and
can internalize microorganisms, likely enhancing pathogen
clearance from the bloodstream [1, 32, 33]. Platelets
stimulated through interactions with microbes or their
signals generate reactive oxygen species that exert direct
antimicrobial activity. Similar to neutrophils and macro-
phages, granules of activated platelets are mobilized by
microtubule assembly, and subsequently secrete. However,
in contrast to leukocyte degranulation directed to intra-
cellular phagolysosomes, platelet degranulation directs the
majority of granule constituents to the extracellular milieu.
Taken together, these characteristics strongly support the
concept that platelets are ancient granulocytes that recog-
nize signals and organisms relevant to settings of infection,
and respond at these sites to confer important host defense
functions.
Platelets bridge innate and adaptive immunity
Platelets make an array of constitutive and inducible
receptors that confer these cells the ability to sense and
respond to hallmark signals of infection. To do so, platelets
express several toll-like receptors (TLRs) that recognize
cognate pathogen-associated molecular patterns (PAMPs).
Thus, platelets function as sentinel cells to detect the
presence of potentially harmful microbes. For example,
quiescent CD41(?) platelets express low levels of TLR2,
TLR4, and TLR9 on their surface. Expression of these
TLRs is signiﬁcantly increased upon platelet activation
[34]. For example, thrombin activation induces signiﬁcant
upregulation of TLR9 expression, and human platelets
express TLR1 and TLR6, particularly in settings of vas-
cular lesions potentially mediated by bacterial infection
[35]. In addition, bacterial LPS causes increased expression
of functional TLR4 in vivo, and such activation and TLR
expression appears to promote tumor-necrosis factor alpha
(TNR-a) expression [36]. Cognasse et al. [37] recently
showed that LPS stimulates platelet release of cytokines,
platelet microbicidal proteins, and kinocidins by way of
TLR4. Of note, incubation of isolated platelets with a
synthetic TLR1/TLR2 agonist directly induces platelet
aggregation and collagen adherence [38]. Stimulation of
platelet TLR2 also increased platelet surface expression
of P-selectin and integrin glycoprotein IIb/IIIa, generation
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neutrophil aggregates in whole human blood.
Despitesuchstructuralandfunctionalevidencerelatingto
roles in innate immunity, platelets have traditionally been
viewed only as cellular fragments incapable of complex
molecular pathways. This view is currently evolving. It is
now known that platelets express constituents of the lipo-
polysaccharide(LPS)receptor-signalingcomplex,including
toll-like receptor-4 (TLR4), TLR2, TLR9, CD14, MD2, and
MyD88. Zhang et al. [39] have demonstrated that LPS
evokes platelet activation and secretion conferred by a
TLR4-mediated process. Here, LPS caused platelet d- and
a-degranulation as shown by ATP release and P-selectin
expression, respectively. The platelet response to LPS was
eliminated in the presence of a-TLR4 antibody, or
using platelets from TLR4 knockout animals. Further,
LPS-induced platelet aggregation and thrombus formation
were mitigated in MyD88 null mice. This LPS-mediated
cGMP upregulation was inhibited by a-TLR4 or TLR4
deﬁciency,implicatingthatplateletsrespondtoLPSthrough
a cGMP/protein kinase G pathway linked to TLR4. These
ﬁndings suggest that platelets are indeed capable of
TLR-mediated sense and response functions important to
effector roles in host defense.
Interestingly, platelet TLR4 has emerged in a putative
new mechanism of host defense. Clark et al. [40] have
suggested that platelet TLR4 detects cognate ligands in
blood, inducing platelet adhesion and subsequent neutro-
phils adherence. This sense and response relay yields
vigorous neutrophil activation and subsequent formation of
neutrophil extracellular traps (NETs). The formation of
bacterial-capturing NETs was predominant in fenestrated
tissues such as the liver sinusoids and pulmonary capil-
laries, where bacterial trapping is most efﬁcient. Hence, it
is possible that platelet TLR4-mediated responses to bac-
teria lead to platelet–neutrophil interactions that enhance
bacterial clearance.
It should be noted that thrombocytes, ancestral nucle-
ated platelets from vertebrates earlier than mammalian or
marsupial, also express TLRs that mediate important host
defense functions. For example, Scott et al. [41] found that
avian thrombocytes express IL-6 and COX-2 mRNA in
response to LPS via a TLR4 pathway. As a result, bioactive
prostaglandin PGE2 is generated. Importantly, the inhibi-
tion of IKK-2 mitigated COX-2 expression, yielding
reduced PGE2 accumulation. These ﬁndings suggest that
MAP kinase pathways are in play in COX-2 and PGE2
production, but not IL-6 expression in these cells. In related
studies, platelets have been shown to enhance neutrophil
oxidative burst in response to Gram-positive as well as
Gram-negative bacteria [42]. Moreover, Bennett et al.
demonstrated that platelets participate in the regulation of
B- and T-lymphocyte- and immunoglobulin-mediated
immune responses via CD40/ligand–CD40 interactions [9].
Similarly, Blumberg et al. [43] hypothesized that soluble
CD40 ligand (CD154) supernatants of stored platelets can
induce cytokines, chemokines, and lipid mediators through
activation of CD40-receptor-bearing cells. Although pre-
liminary, such themes support the emerging concept that
platelets actively participate in bridging the innate and
adaptive immune response to infection.
Taken together, the expression of various TLRs, and an
ability to bridge interactions with neutrophils and perhaps T
and B cells suggests mechanisms through which platelets
may directly or indirectly detect bacterial pathogens by
recognition of molecular patterns and early warning signals
of infection, and then contribute to optimization of immune
response.
Platelets sense bacterial infection of endothelium
Beyond their ability to detect microbes themselves, platelets
are exquisite sensors for signals of endothelial infection.
Endothelial cells damaged by infection undergo changes in
surface protein repertoires and secretory proﬁles thatactivate
platelet responses. Distinct platelet receptors sense agonists
and bind to ligands on the surface of activated endothelial
cells, or exposed subendothelium due to infection or tissue
invasion.Signalsdetectedbyplateletmembraneglycoprotein
(GP)receptorsinclude:collagen[(GPVIanda2b1(VLA-2or
GPIa-IIa), ﬁbronectin (a5b1 or VLA-5), laminin (a6b1o r
VLA-6), von Willebrand factor (GPIb-IX-V), vitronectin
(integrinaVb3),andthrombin] [1,6–10].Contactwithblood
ormicrobes induces tissuefactor release from subendothelial
stroma, thereby catalyzing thrombin production [1, 44–46].
Thrombinisapotentplateletagonist[1,7,17],whichinduces
expression of ensuing platelet receptors, including the
ﬁbrinogen receptor [integrin aIIbb3( G P I I b - I I I a ) ] .A c t i v a t e d
platelets also undergo metamorphosis from a discoid to
ameboid form, along with microtubule assembly and granule
reorganization [47, 48]. Degranulation follows, releasing an
array of bioactive molecules, including ADP from d-gran-
ules, and generating thromboxane A2 and platelet-activating
factor (PAF) through activation of membrane phospholipase
A2 [1, 7, 17].These potent agoniststrigger subsequent waves
ofplateletactivationatsitesoftissuecolonization,promoting
an accumulation of antimicrobial proteins from a-granules
([49]; also see below). In addition, P-selectin (CD62P) is
exposed on the activated platelet plasma membrane, poten-
tiating leukocyte rolling and eventual recruitment to these
sites.
Platelets accumulate at sites of tissue infection
Platelets are the earliest and most numerous cells to
accumulate at sites of vascular infections [50–60],
Platelets in antibacterial host defense 527including: infective endocarditis, suppurative thrombo-
phlebitis, mycotic aneurysm, septic endarteritis, catheter
and dialysis access site infections, and infections of vas-
cular prostheses and stents. The rapid and intensive
accumulation of platelets at these sites has long been
known. In 1886, Osler [61] reported perhaps the ﬁrst
observation of platelets rapidly coating ﬁlaments intro-
duced into animal blood vessels. Subsequently, Cheung
and Fischetti [62] and others demonstrated that platelets are
the ﬁrst cells to adhere to indwelling vascular catheters.
Similarly, platelets rapidly adhere to cardiac valve pros-
theses and vascular stents [60], and are abundant cells in
early phases of endocarditis vegetations in rabbits and
humans. Once again, such rapid and targeted responses
to sites of tissue injury or microbial invasion support a
speciﬁc role for platelets in host defense.
Subversion of platelet functions by bacterial pathogens
Vascular infections caused by virulent bacterial pathogens
such as Staphylococcus aureus have traditionally been
considered to proceed through multiple phases: (1) adher-
ence of hematogenous pathogens to normal or compromised
vascular endothelium (e.g., rheumatic conditions, proximal
to artiﬁcial device such as a stent or prosthetic valve, etc.);
(2) endothelial cell expression of selectins and secretory
agonists that promote platelet activation, adhesion, and
platelet/ﬁbrin matrix formation [1, 63, 64]; and (3) ensuing
deposition of circulating platelets in response to successive
waves of agonists (e.g., thromboxane A2, ADP, PAF), or
ligands (e.g., integrin aIIbb3) associated with secondary
plateletactivation[1,7,17].Lessvirulentpathogens,suchas
viridans streptococci, are thought to require pre-existing
abnormalities or injury to endothelial surfaces to initiate
endovascular infection through indirect pathways:
(1) ﬁbrinogen-mediated adherence to intact or abnormal
vascular endothelium or non-bacterial thrombotic vegeta-
tions [1, 54]; (2) vascular endothelial cell expression of
platelet ligands and agonists (see above); and (3) further
platelet/ﬁbrin deposition and evolution of the lesion [1, 7,
10]. In either case, platelets localize to sites of infection of
the vascular endothelium, and represent the most rapid and
abundant inﬂammatory cells that respond to endothelial cell
damage or microbial colonization. Thus, platelets represent
the earliest opportunity for inﬂammatory responses to
intercede in host defense against vascular infection.
Studies over the last two decades have clearly demon-
strated that platelets have explicit roles in antimicrobial
host defense. Yet, historically, platelets were viewed as
promoting the establishment and evolution of endovascular
infection [1, 7, 53, 65, 66]. Early studies were interpreted
to suggest that platelets facilitate microbial adhesion to
ﬁbrin matrices or endothelial cells in vitro [66]. Subsequent
data demonstrated that bacterial and fungal pathogens can
aggregate human and rabbit platelets in vitro [67–69].
Herzberg et al. [71] hypothesized that streptococcal bind-
ing to and aggregation of platelets may increase virulence
of these strains in experimental animal models of endo-
carditis. Platelet aggregation has also been hypothesized to
be detrimental to the host, since massive endovascular
vegetations can be associated with clinical complications
such as emboli and infarcts [72]. Finally, some investiga-
tors have suggested that platelet aggregation and enclosure
of microorganisms in platelet–ﬁbrin matrices may protect
pathogens from antibiotics or clearance by neutrophils or
other leukocytes [73].
Platelets have known antimicrobial structures and
functions, and interact with bacteria and other pathogens
directly and indirectly. Moreover, no studies substantiate
the concept that platelets inherently facilitate microbial
pathogenesis or inhibit the immune response. Rather,
evolutionary adaptation would have almost certainly
selected against such cells. Therefore, the consequences of
platelet interaction with bacteria or other pathogens likely
rests on the efﬁcacy platelet antimicrobial mechanisms or
their interaction with other immune defenses versus the
ability of a pathogen to circumvent or survive in the face of
such mechanisms.
Platelets interact with bacterial pathogens
Platelets interact with all kingdoms of microbial patho-
gens, including viruses, bacteria, fungi, and protozoa.
However, platelets interact with distinct types of patho-
gens in different ways. Such interactions may be direct or
indirect, and can yield signiﬁcant antimicrobial responses
and mechanisms. As thorough reviews of such interac-
tions have been previously compiled [1, 6–10, 17], the
following discussion focuses on interactions between
platelets and human bacterial pathogens. These interac-
tions are viewed with an emphasis on key themes and
recent advances in understanding this host–pathogen
relationship.
Key events in platelet–bacterial relationships
Platelets engage bacterial pathogens directly and indirectly
in vitro and in vivo. The earliest methodical studies of such
relationships were those of Clawson and White [73–76]. In
their studies, bacterial pathogens were shown to adhere to,
aggregate, activate, and prompt degranulation of human
and other mammalian platelets. Typically, the sequence of
events associated with platelet-bacterial interaction pro-
ceeds through distinct and progressive phases: (1) direct
contact, (2) morphogenesis, (3) initial aggregation, and (4)
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platelets undergo a signiﬁcant shape change from resting
discoid cells to ameboid forms that form multiple pseu-
dopodia. This shape transition typically occurs well in
advance of platelet aggregation, leading to platelet micro-
tubule organization such that granules are mobilized from
the platelet perimeter to the cytoplasm [75]. This organi-
zation of granules precedes platelet degranulation [76] and
secretion of an array of host defense molecules (also see
below).
Diverse bacterial genera, and even different species of
the same genus, may differentially adhere to, activate,
aggregate, and induce platelet degranulation. For example,
Clawson and White, and many platelet scientists since,
have shown that Streptococcus pyogenes, Staphylococcus
aureus, Enterococcus faecalis, and Escherichia coli rapidly
adhere to and promote aggregation of human platelets in
vitro [73–76]. Beyond these organisms, diverse pathogenic
species interact with and aggregate platelets in vitro,
including Fusobacterium [77], Listeria [78], Mycobacte-
rium [79], Pseudomonas [80], Salmonella [81, 82], and
Yersinia [83]. In contrast, bacteria that gain entry into the
bloodstream, including Staphylococcus epidermidis and
Streptococcus pneumoniae, do not trigger irreversible
platelet aggregation [74]. Thus, the consequences of bac-
terial interactions with platelets adherence, activation, and
antimicrobial response proﬁle likely signiﬁcantly inﬂuence
host defense versus virulence of a given pathogen. The
following section considers platelet interactions with
staphylococci, streptococci, and notable Gram-negative
pathogens such as prototypic bloodstream pathogens in
these respects.
Staphylococcal interactions with platelets
Species of the genus Staphylococcus are currently the
most frequent etiologic agents of infective endocarditis
([84–86]), and the second most frequent agents of bacter-
emia [87–89]. The incidence of S. aureus invasive
infections continues to increase sharply [90], and now
occurs in up to 20,000 new patients per year in the United
States alone [91–93]. Even with modern advances in anti-
staphylococcal therapy and endovascular surgery methods
and devices, the 1-year mortality of these infections
approximates 40% [86–93]. More concerning still is the
global burgeoning in S. aureus resistance to conventional
antimicrobial agents and strategies [94, 95].
Aside from Streptococcus spp., the interactions of
platelets and with staphylococci, and in particular S. aur-
eus, have been the most well-characterized. Traditionally,
investigations focused on two distinguishable but comple-
mentary facets of this relationship: (1) toxins and other
secretory and capsular components; and (2) surface protein
mediators of platelet activation.
Perhaps the most thoroughly studied S. aureus toxin or
secretory factor interacting with platelet function is alpha
(a) toxin. The expression of this exotoxin is accessory-gene
regulon (agr)-regulated, and targets platelets as well as
other host cells. The toxin is believed to interact with the
cell membrane of platelets, erythrocytes, and even some
leukocytes, inducing injury and ultimately cellular lysis.
Notably, Bayer et al. [96] found a paradoxical relationship
between S. aureus a-toxin expression and virulence in vivo,
speciﬁcally pertaining to platelet interactions. These
authors evaluated the impact of a-toxin in experimental
endocarditis in vivo using isogenic strains differing in
expression of functional versus mutant forms of a-toxin. In
vitro, the parental a-toxin induced platelet lysis and
secretion of platelet microbicidal proteins (PMPs; see
below) active against S. aureus. In experimental endocar-
ditis, the S. aureus strains producing either minimal a-toxin
or non-functional a-toxin were signiﬁcantly less virulent in
vivo than wild-type strains. Paradoxically, an isogenic
strain constructed to overexpress a-toxin was also signiﬁ-
cantly less virulent than its parental counterpart in this
animal model. Moreover, increased a-toxin expression
correlated with greater PMP release by exposed platelets.
Together, these outcomes indicated that expression of
excessive a-toxin leads to increased PMP release secondary
to either platelet secretion or lysis, thus increasing anti-
staphylococcal platelet responses and reduced virulence in
experimental endocarditis. This phenomenon is referred to
as a ‘‘Goldilocks Effect’’ in S. aureus–host relationships.
Regarding non-soluble mediators, most studies focusing
on interactions of platelets with S. aureus have focused on
surface proteins expressed by the pathogen. In early
experiments, Hawiger et al. [97] demonstrated that
S. aureus triggers platelet morphogenesis, aggregation, and
degranulation in a pathway involving S. aureus protein A,
host IgG, and platelet Fc receptors. Considerable work
since then has revealed that this organism employs several
factors to interact with platelets when it is advantageous to
do so. For example, S. aureus surface proteins that mediate
direct or indirect platelet interactions include clumping
factors A and B (ClfA/ClfB), ﬁbronectin-binding proteins A
and B (FnbpA/FnpbB), protein A (Spa), serine-aspartate-
repeat protein E (SdrE), serine-rich adhesin for platelets
(SraP), extracellular ﬁbrinogen-binding protein (Efb), and
other molecules. A meritorious review of these S. aureus
surface proteins, and homologous factors of other patho-
gens has been compiled by Fitzgerald et al. [10]. Hence,
the following comments focus on fundamental themes
regarding such surface proteins and recent studies of their
platelet interactions.
Platelets in antibacterial host defense 529In complementary studies, Sullam et al., Yeaman et al.,
and Bayer et al. used classical aggregometry and multi-
color ﬂow cytometry to investigate the molecular and
cellular interactions between staphylococci and platelets
[98–100]. These studies revealed that staphylococci adhere
directly to human or rabbit platelets in vitro, in the absence
of plasma. Notably, the S. aureus-to-platelet ratio directly
inﬂuences the extent and velocity with which platelet
aggregation follows after initial contact [99]. Additionally,
rapid adherence to platelets occurs via saturable and
reversible kinetics that are indicative of receptor–ligand
interactions. As multiple S. aureus surface proteins can
mediate platelet interactions, such ﬁndings suggest that
each receptor–ligand interaction may occur independently
as well as cooperatively. Recently, Siboo et al. [101]
characterized a serine-rich protein, SraP, that mediates
adhesion of S. aureus to platelets. Moreover, a mutant
deﬁcient in SraP has a reduced virulence phenotype in
rabbit models of infective endocarditis. This protein is
227 kDa and, similar to its streptococcal homolog GspB,i s
predicted to contain unusual N-terminal signal sequences,
two serine-rich repeat domains, and a C-terminal motif
likely required for cell wall anchoring (LPDTG; also see
below).
In related studies, Niemann et al. [102] reported that
platelet quality inﬂuences S. aureus–platelet interactions.
In their investigation, platelets obtained from patients with
speciﬁc inherited deﬁciencies in platelet granule contents
(e.g., a-d storage pool disease or Gray platelet syndrome)
were assessed for interactions with S. aureus. Interestingly,
CD36 (thrombospondin receptor), GPIIb/IIIa (a major
platelet integrin receptor), and CD62 (P-selectin) did not
play signiﬁcant roles as receptors for S. aureus. Further,
platelet activation by ADP did not promote S. aureus
adhesion, although platelets were found to be bound by
ﬁbrinogen. On the contrary, soluble ﬁbrin (but not ﬁbrin-
ogen), clumping factor A and thrombospondin-1 increased
platelet binding to S. aureus. Thus, these latter molecules
likely act as bridging matrices that promote S. aureus-
platelet interactions.
Such ﬁndings highlight an emerging theme increasingly
evident in interactions between staphylococci and platelets:
S. aureus and other staphylococci exploit plasma cofactors
to facilitate interaction with platelets when advantageous,
or limit interactions to subvert platelet antimicrobial
responses. For example, S. aureus interacts with vascular
endothelium and platelets via ﬁbrinogen bridging [103,
104]. Bayer et al. [100] found that S. aureus can induce
aggregation of rabbit platelets via a ﬁbrinogen-dependent
mechanism independent of GPIIb/IIIa. Moreover, ﬁbro-
nectin is not signiﬁcantly involved in staphylococcal
adhesion to quiescent platelets. In contrast, ﬁbronectin does
appear to faciliate S. aureus interactions with activated
platelet–ﬁbrin clots or stimulated endothelium [105].
Likewise, Hermann et al. [106] found that S. aureus
exploits thrombospondin to adhere to activated platelets
and extracellular matrices. Loughman et al. [107] further
demonstrated that cognate immunoglobulin directed
against clumping factor (ClfA) can modulate S. aureus–
platelet adherence. Alternatively, S. aureus has been shown
to bind to platelets through mechanisms involving protein
A and the platelet C1q complement receptor, gC1qR/p33
[108]. As gC1qR/p33 is expressed upon activated but not
quiescent platelets, S. aureus may speciﬁcally exploit
adhesion to activated platelets. Such examples highlight
the emerging theme that S. aureus and platelets interact
directly and indirectly through multiple soluble and cell-
associated bridging ligands.
Other new evidence indicates that the serine-aspartate-
repeat protein G (SdrG), a ﬁbrinogen-binding protein
present in a majority of clinical S. epidermidis isolates, is
sufﬁcient to enable this organism to adhere to and aggre-
gate platelets [110]. Brennan et al. employed surrogate
genetics to shown that Lactococcus lactis expressing SdrG
induces platelet aggregation in a manner dependent on both
ﬁbrinogen and IgG, and on the platelet IgG receptor
FccRIIa. Pre-exposure of SdrG-expressing L. lactis to
b-chain ﬁbrinopeptide reduced platelet aggregation; sub-
stantiating the interpretation that ﬁbrinogen is a bridging
intermediate. Interestingly, in their studies, such aggrega-
tion was inhibitable by GPIIb/IIIa antagonists as well as by
aspirin.
Lastly, a new role for S. aureus–platelet interactions has
recently been put forth. Yousseﬁan et al. [109] reported
that platelets can actively phagocytose Staphylococcus
aureus. Internalization of the organism corresponded to
morphological transition consistent with platelet activation.
In turn, platelet activation recursively enhanced S. aureus
internalization. Although these ﬁndings support the
emerging view that platelets are active host defense cells, it
remains to be seen whether platelet antimicrobial responses
are related to internalization, or result from degranulation
of microbicidal proteins to target extracellular pathogens
(see below).
Streptococcal interactions with platelets
Pathogenic members of the genus Streptococcus are typi-
cally viewed as human commensal organisms that can gain
entry to the bloodstream. Until recently, streptococci
(e.g., Streptococcus sanguis) were viewed as the most
common etiologic agents of infective endocarditis (IE);
S. aureus has now assumed that role. Nonetheless, the fact
that most humans experience transient streptococcal bac-
teremia regularly without the onset of endovascular
infections or infective endocarditis suggests there are
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platelets and streptococci. In this respect, a substantial
body of literature has been published investigating the
ability of various streptococcal species to interact with
human platelets. The following section illustrates com-
parative themes and recent insights into this relationship.
Traditionally, streptococci have been found to interact
with platelets through a variety of mechanisms and
molecular intermediates. Herzberg et al. reported that
certain viridans streptococci such as Streptococcus sanguis
adhere directly to the platelet surface via a 150-kDa two-
domain adhesin [70, 71, 111]. Zimmerman et al. [112]
showed that St. pneumoniae aggregates platelets only in the
presence of cognate anti-pneumococcal antibody in vitro.
As in S. aureus, Ford et al. [113] demonstrated that
St. sanguis aggregates platelets through a ﬁbrinogen path-
way involving platelet integrin GPIIb/IIIa receptor.
Similarly, platelet aggregation and degranulation prompted
by St. pyogenes can be mediated by ﬁbrinogen [114], while
Johnson and Bowie [115] reported that that some group C
streptococci indirectly with platelets through the von
Willebrand factor.
New evidence derived from contemporary methods in
microbial genetics and ﬂow cytometry have greatly
advanced our understanding of streptococcal–platelet
interactions. As seen in S. aureus, such ﬁndings illustrate
how streptococci interact with platelets directly and indi-
rectly. For example, although St. gordonii has been known
to interact with platelets, new insights are emerging indi-
cating that very speciﬁc intermediaries result in its
adherence to and activation of platelets. Using surrogate
genetics, Kerrigan et al. [116] demonstrated that overex-
pression of St. gordonii SspA or SspB (antigen I/II family
proteins) in null Lactococcus lactis enabled the latter
organism to induce platelet aggregation, but not adhere to
platelets. This ﬁnding suggests that the Ssp-family proteins
may mediate soluble activation of platelets. In contrast,
St. gordonii Hsa protein (a homolog of GspB) facilitated
platelet adhesion. Thus, St. gordonii appears to have dis-
tinct molecular mechanisms for platelet adhesion and
platelet aggregation. Given its ability to cause IE in
humans, it is intriguing to speculate that regulated
expression of these or other platelet interaction molecules
may determine how St. gordonii or other streptococcal
pathogenesis interact with platelets to exploit these host
cells, or avoid platelets if it is advantageous to subvert
antimicrobial responses of these cells.
Perhaps the most novel insights into streptococcal–
platelet interactions in recent years have emerged from
important studies performed in the Sullam laboratory. Prior
studies by Sullam et al. found that viridans group strepto-
cocci aggregate human platelets via direct platelet binding,
as well as through plasma cofactors [68, 98, 117]. For
example, the aggregation of human platelets by some
streptococci requires organism-speciﬁc IgG, which pre-
sumably interacts with the platelet 40-kDa FccRII surface
receptor [117]. Ensuing studies by Bensing et al. [118]
identiﬁed two genetic loci in St. mitis that appeared to
mediate binding to human platelets in vitro. These dis-
coveries suggest that interactions between streptococci and
platelets occurs via speciﬁc receptor–ligand interactions.
More recently, this group demonstrated that two platelet-
binding adhesins from St. mitis—PblA and PblB—are
encoded as a results of lysogenic prophage integration
[119]. Interestingly, translocation of these proteins to the
bacterial cell wall for surface display requires holin or lysin
gene expression. The export of these proteins apparently
requires membrane permeabilization, enabling anchoring
to cell wall choline rather than conventional anchoring
motifs. More importantly, loss of PblA and PblB expres-
sion yields decreased platelet binding in vitro, and reduced
virulence in experimental IE. More recent reports from
this group indicate that PblA and PblB proteins target
a2-8-linked sialic acids on ganglioside GD3 for adhesion to
human platelets [120]. Thus, this body of work reveals how
streptococci appear to interact with human platelets
through highly sophisticated molecular and cellular
determinants.
In parallel to their studies above, the Sullam laboratory
investigated the role of cell surface glycoprotein GspB in
St. gordonii adherence to platelets [121]. Isogenic strains of
St. gordonii M99 with or without gspB expression were
evaluated in models of infection in rats, independently and
in strain competition studies. When infected independently,
cardiac vegetation, kidney, and spleen tissues had signiﬁ-
cantly lower densities of the null mutant as compared with
the wild-type strain. Further, in competition studies in
which both strains were co-infected, the wild-type strain
achieved signiﬁcant CFU densities in these tissues, while
the gspB mutant was not detectable. These ﬁndings
strongly suggest that GspB confers an important platelet
binding function to this organism that may be important to
virulence in vascular pathogenesis. It is also noteworthy
that prior studies by this laboratory demonstrated that
glycosylation of GspB is mediated in part by Gly and Nss
proteins encoded in the secY2A2 locus [122]. Comple-
mentary genetic and protein analyses revealed that Gly,
Nss, Gtf, and Orf4 are involved in the intracellular glyco-
sylation and solubility of GspB. Thus, extracellular access
and glycosylation state appear to be key to the ability of
GspB to promote adhesion of St. gordonii to human
platelets.
Bacteria must circumvent or subvert the signiﬁcant
antimicrobial mechanisms of platelets to exploit these cells
in virulence strategies. Alternatively, it is possible that
profusive platelet responses to streptococci may contribute
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For example, Ohba et al. [123] demonstrated in mice that
St. intermedium or St. constellatus injected intravenously
triggered platelet-mediated responses mirroring septic
shock. In animals primed with muramyldipeptide, whole
organisms introduced into the vascular compartment
caused a rapid anaphylactoid-like shock response. How-
ever, in non-primed animals, little or no sign of shock was
observed. Interestingly, the cardinal signs of shock
response were preceded by platelet degranulation and
5-hydroxytryptamine (5HT) secretion, as well as comple-
ment ﬁxation yielding activated C5. The septic-shock-like
paradigm was mitigated by a complement-C5 inhibitor.
Collectively, these results suggest that platelets respond to
streptococci by activating host defense mechanisms
including degranulation and complement ﬁxation. How-
ever, certain pathogens may hyperstimulate platelets such
that activation, degranulation, complement ﬁxation, or
other immune responses occur to an excessive degree that
results in non-optimal host outcomes.
The studies highlighted above illustrate the emerging
theme that distinct streptococcal species and phenotypes
vary in interactions with human platelets. It is highly
likely that distinct pathogens have co-evolved with hosts
so as to optimize their interactions with platelets for ﬁt-
ness advantages. For example, early studies demonstrated
that St. pyogenes can prompt platelet aggregation perhaps
by a molecular mimic of collagen [124]. In contrast, St.
pneumoniae appears to optimally induce aggregation by
way of an antibody-dependent mechanism [112]. In con-
trast, St. agalactiae expresses a ﬁbrinogen-binding protein
known as FbsA that confers adhesion and aggregation of
platelets mediated by ﬁbrinogen and IgG [125]. These and
other theme-and-variation examples illustrate how patho-
gens such as streptococci or staphylococci that often
encounter platelets and other host defenses in the blood-
stream have necessarily evolved diverse mechanisms to
interact with platelets. It is conceivable these some
adaptations may provide advantages to enable pathogens
to circumvent or subvert platelet-mediated host defense
mechanisms.
Gram-negative pathogen interactions with platelets
Relatively little is known about platelet interactions with
Gram-negative pathogens as compared with Gram-positive
counterparts. Other reviews offer comprehensive perspec-
tives of such comparisons [1, 6–10]. Here, the following
discussion highlights the current view that Gram-negative
pathogens capable of entering the bloodstream have
important interactions with platelets that likely contribute
to the difference between virulence and host defense.
One of the best examples of this theme can be consid-
ered from studies assessing interactions between platelets
and Pseudomonas aeruginosa or Yersinia species. Cout-
inho et al. [126] reported that the major phospholipase C
from P. aeruginosa caused platelet aggregation in a dose-
dependent manner. Interestingly, the use of heat-denatured
enzyme, or nitrophenol-phosphoryl-choline (inactive sub-
strate of phospholipase C), revealed that enzymatic
function of phospholipase C was required for platelet
activation. Furthermore, ADP, epinephrine, collagen, or
ristocetin were unable to inhibit phopholipase C activation
of platelets, and lack of inhibition by aspirin or nordihy-
droguairetic acid suggested that the mechanism was
independent of prostaglandin or lipooxygenase pathways.
In recent studies, Machado et al. [127] examined the
role of P. aeruginosa phospholipase A2 on platelet acti-
vation in a mouse model of infection. Pseudomonal
phospholipase A2 is encoded by the ExoU gene, and is a
well-established cytotoxin. In a pneumosepsis model, mice
instilled intratracheally with ExoU-producing P. aerugin-
osa caused a signiﬁcantly higher mortality rate, reduced
leukocyte concentration, higher platelet concentration, and
higher hematocrit than animals infected with the exoU null
mutant. Moreover, platelets from mice infected with the
wild-type strain were signiﬁcantly more activated than the
null mutant, as indicated by P-selectin expression, platelet-
derived microparticle detection, and immunoassay detec-
tion of thromboxane A2 (TXA2). Lung and kidney
histopathology of wild-type-infected mice revealed
thrombus formation that was absent in null-infected ani-
mals. Based on these observations, it appears that
activation and thrombus formation in response to phos-
pholipase A2-producing strains of P. aeruginosa may
contribute to pathogenesis.
Yersinia species also appear to interact with platelets in
ways that are likely to inﬂuence to the consequences of
pathogenesis versus host defense. Recent studies by
Shepel et al. [128] examined interactions of Y. entercoli-
tica and Y. pseudotuberculosis with platelets in vitro.
From prior studies, Y. pseudotuberculosis is known to be
capable of entering platelets and inducing platelet aggre-
gation via a mechanism involving expression of the inv
invasin gene. In the recent studies, both Yersinia strains
were engineered to express green ﬂuorescent protein to
enable real-time assessment of interaction with platelets
by ﬂow cytometry. While both strains adhered to platelets,
only Y. pseudotuberculosis caused platelet activation and
aggregation. Moreover, Y. enterocolitica bearing virulence
plasmid pYV? interacted with platelets, while a pYV-
strain did not. Transmission electron microscopy revealed
that Y. pseudotuberculosis expressing the inv gene was
able to invade platelets. However, Y. enterocolitica or
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the extracellular surface of platelets.
An interesting recent study, Bhat et al. [129] analyzed
potential correlates of organism-speciﬁc infection, platelet
response, and thrombocytopenia in low birth weight neo-
nates with sepsis. Over a 5-year period, very low birth
weight neonates (\1,500 g) in a level-three intensive care
unit were prospectively evaluated for sepsis. Gram-positive
sepsis occurred in 20% of these patients, Gram-negative in
71%, and fungal sepsis in 8.6%. Thrombocytopenia was
observed in 67% of patients overall. The frequency and
duration of thrombocytopenia were signiﬁcantly greater in
Gram-negative and fungal infections; persistent bactere-
mia, multiorgan failure, and mortality were signiﬁcantly
greater in thrombocytopenic patients. Importantly, multi-
organ failure and mortality were directly correlated with
duration of thrombocytopenia. On multiple logistic
regression analysis, the worst prognostic indicators were a
severe drop in platelet count at onset of sepsis, a low
platelet nadir, prolonged duration of thrombocytopenia,
and need for platelet transfusion. Given the majority of
poor outcomes correlating with Gram-negative infections,
molecular interactions of platelets with such organisms,
and the virulence versus host defense consequences of
these interactions, remain areas that merit considerable
focused research.
Platelet mechanisms of host defense against pathogenic
bacteria
Chronologic overview
Historically, platelets have been viewed as contributing to
microbial pathogenesis. However, it is now evident that
platelets have explicit structures and functions that con-
tribute signiﬁcantly to host defense against infection. Over
the past decade, contemporary techniques in host–pathogen
relationships, protein chemistry, and molecular biology
have been applied to identify and deﬁne the molecular
effectors and mechanisms of platelet host defenses. Plate-
lets interact rapidly, directly, and speciﬁcally with bacterial
pathogens, liberate an array of direct antimicrobial mole-
cules, and shape adaptive immune responses. Detailed
reviews of such platelet mechanisms of molecular and
cellular antimicrobial defense have been reviewed else-
where [1, 6–10].
Perhaps the earliest mention of platelet antimicrobial
function was in 1887, when Fodor reported a heat-stable
bactericidal capacity of serum, termed b-lysin, distinct
from heat-labile or a-lysin complement proteins [130].
Later, Gengou demonstrated that b-lysin bactericidal
activity of serum derived from cells involved coagulation,
and was independent of complement [131]. In 1938,
Tocantins reviewed studies that suggested possible immune
functions of platelets [5]. Subsequent studies by Hirsch
demonstrated that platelets, not classical leukocytes,
conferred bactericidal activity to rabbit serum [132].
Eventually, many other noted investigators, including Jago
and Jacox [133], Weksler [134], Kahn et al. [135], Czup-
rynski and Balish [78], and Miragliotta et al. [136] afﬁrmed
that platelets exert in vitro bacteriostatic and/or bactericidal
effects versus many pathogens, including Bacillus, Staph-
ylococcus, Listeria, Salmonella, and many other organisms.
In subsequent studies, numerous investigators studied
platelet-speciﬁc molecule(s) that might be associated with
the antimicrobial action of serum [133, 137–144]. Among
the earliest of these reports, Myrvik [140] demonstrated
that two platelet-derived serum factors were responsible for
killing of Bacillus subtilis. Jago and Jacox [133] and
Myrvik and Leake [141] conﬁrmed these ﬁndings. Later,
Donaldson et al.[142], Johnson et al. [143], and other
groups isolated putative b-lysins from rabbit serum that
exerted S. aureus- or B. subtilis-speciﬁc killing. In parallel,
Weksler and Nachman [144] isolated two cationic proteins
from platelets with molecular masses of 10 and 40 kDa that
were bactericidal in vitro versus B. subtilis and S. aureus
strains, respectively. In each of the above studies, the
platelet antimicrobial effector molecules were identiﬁed as
being small and cationic, with masses ranging from 6 to
40 kDa. Tew et al. [145] found that b-lysin proteins were
released from rabbit platelets by stimulation with thrombin,
establishing a potential link between tissue injury and
platelet liberation of host defense effectors. Likewise,
Dankert et al. [146, 147] also suggested that platelets
release platelet-associated bactericidal substances follow-
ing thrombin stimulation. Darveau et al. [148] identiﬁed
peptide fragments of human platelet factor-4 with anti-
microbial activity in combination with antibiotics against
certain Gram-negative bacteria.
Platelet microbicidal proteins and kinocidins
In recent years, the molecular effectors of platelet antimi-
crobial response have been the topic of intensive
investigation. By convention, the term platelet microbicidal
proteins (PMPs) is used to include PMPs, thrombin-
induced PMPs (tPMPs), and derivatives thereof termed
thrombocidins. Importantly, a subset of PMPs have been
discovered to be classical chemokines that have direct
microbicidal activity. These polypeptides are termed kin-
ocidins, reﬂecting their dual chemokine and microbicidal
effector functions [149]. Important investigations by Cole
et al. [150], Yang et al. [151], and others have subsequently
reinforced this discovery. Detailed structures and mecha-
nisms of PMPs and kinocidins are available in other reports
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PMPs and kinocidins differ in several important respects
from classical antimicrobial peptides such as defensins.
The family of PMPs and kinocidins can be found in
human and other mammalian platelets [1, 7, 152–163].
Two predominant PMPs (tPMPs 1 and 2) are liberated from
platelets upon thrombin stimulation [154–156]. These, like
PMPs and kinocidins, exist as native species that appear to
undergo proteolytic cleavage in contexts of infection.
For example, Yount et al. [156, 157] and Yeaman et al.
[157–159] have shown that PMPs are cleaved into auton-
omous but complementary functional domains by context-
relevant proteases such as thrombin. Likewise, Anderson
et al. [164] have conﬁrmed these previous ﬁndings that
fragments of mammalian platelet factor-4 and related
molecules can also have antimicrobial efﬁcacy. The fact
that thrombin is generated at sites of vascular infection, and
is a strong inducer of platelet degranulation, illustrate how
PMP and kinocidin release is coordinated with response to
endovascular host defense [159]. Mass spectroscopy has
demonstrated that PMPs and kinocidins range in size from
approximately 6.0 to 9.0 kDa [1, 158, 181]. Cloning and
amino acid analyses afﬁrm these molecules to have a net
cationic charge, mediated by an enrichment of basic resi-
dues lysine and arginine. Molecular mass, sequence, lysine
content, and other features distinguish PMPs and kinoci-
dins from classical defensins [1, 154, 158] overall.
However, recent discoveries have identiﬁed a multidi-
mensional signature—termed the c-core—that uniﬁes these
and other host defense molecules by way of physico-
chemical themes as distributed across their 3D shape [161,
163]. To summarize a considerable body of recent litera-
ture, PMPs, kinocidins, fragments and synthetic congeners
thereof have repeatedly been shown to exert strong in vitro,
ex vivo, and in vivo efﬁcacy against Gram-positive and
Gram-negative bacteria and fungi [1, 158, 165]. Of note,
Azizi et al. [166] and Bayer et al. [96] have also shown that
speciﬁc pathogens or puriﬁed staphylococcal a-toxin
prompt speciﬁc PMP or kinocidin release proﬁles from
platelets in vitro. These and other aspects of PMPs and
kinocidins have been reviewed elsewhere [1, 158]. Thus,
the remainder of this report focuses on key themes and
potential correlates of these molecular effectors of host
defense against bacterial infection.
PMPs and kinocidins derive from distinct genetic
lineages
The repertoire of PMPs and kinocidins is now known to
represent multiple molecular species representing several
genetic lineages. Tang et al. [152] ﬁrst isolated and iden-
tiﬁed antimicrobial peptides from human platelets that are
homologous to those in other mammals. Today, an array of
host defense effector peptides is known to be liberated
from human platelets upon thrombin stimulation. The array
of PMPs and platelet kinocidin molecules includes: platelet
factor-4 (PF4), platelet basic protein (PBP) and its prote-
olytic derivatives, connective tissue-activating peptide-3
(CTAP-3) and neutrophil-activating peptide-2 (NAP-2),
RANTES (‘‘released upon activation, normal T cell
expressed and secreted’’), thymosin-b-4 (Tb-4), and ﬁbri-
nopeptides A and B (FP-A and FP-B) [152, 153].
Importantly, these antimicrobial effector proteins arise
from ﬁve genetically-distinct lineages in humans and other
mammals: (1) PF-4 and variants; (2) PBP and its proteo-
lytic derivatives CTAP-3 and NAP-2; (3) RANTES; (4)
Tb-4; and (5) ﬁbrinopeptides. Therefore, potential defects
or deﬁciencies in one given lineage are not likely to neg-
atively impact others. Such redundancy may have played
an important role in evolution of mammalian immunity
against bacterial and other microbial pathogens.
Kinocidins can be classiﬁed relative to their chemokine
nomenclature. For example, PF-4, PBP, CTAP-3, and
NAP-2 are a-kinocidins, as they possess CXC-chemokine
motifs. In contrast, RANTES is a b-kinocidin, containing
a CC-chemokine motif. The direct antimicrobial activities
of these proteins were initially identiﬁed by Tang et al.
[152] and Yeaman et al. [155]. Krijgsveld et al. [167]
subsequently suggested that carboxy-terminal di-amino
acid truncated versions of NAP-2 or CTAP-3 also exerted
antimicrobial activity in vitro. Native PMPs and kinoci-
dins can be further processed in the context of infection or
tissue injury after liberation from platelets. Thrombin
(a serine protease), platelet-derived proteases, and prote-
ases activated by tissue injury, phagocytes (e.g., cathepsin
G), or inﬂammation (e.g., plasmin) may process native
PMPs and kinocidins, generating multiple antimicrobial
peptide subspecies [1, 157, 161]. Recently, molecular
studies of structure–activity relationships among PMPs
and kinocidins have discovered fascinating new insights
into the likely roles of these molecules in optimizing host
defense [156, 161, 162]. For example, amino acid
sequencing and mass spectrometry have demonstrated
distinct N-terminal polymorphism variants of rabbit PMP-
1 from unactivated versus thrombin-stimulated platelets,
respectively, that arise from a single common PMP-1 pro-
peptide [156]. Alternatively, PMPs and kinocidins respond
to microbial virulence factors such as proteases by
deploying domains with optimized antimicrobial efﬁcacy
versus cognate pathogens in contexts of infection [1, 157].
Yeaman et al. invented a novel platform of anti-infective
agents that integrate the architecture and processing of
PMP and kinocidin proteins which have autonomous yet
complementary antimicrobial effector domains that are
deployed via disassembly in context [157, 168]. Sup-
porting this concept, Sieprawska-Lupa et al. [169] have
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reolysin and V8 protease cleave the antimicrobial peptide
LL-37. Finally, discoveries of structural, functional, and
evolutionary relationships among host defense peptides,
classical toxins, and like molecules now afford a new
understanding of host defenses, and opportunities to
develop anti-infective peptides with minimal host cyto-
toxicity [170].
It is now known that monocytes have been shown to
express PMPs and kinocidins with antimicrobial activity.
For example, the PMP and a-kinocidin platelet basic pro-
tein (PBP) is also expressed in human monocytes [171].
Most recently, studies have demonstrated that exposure of
human monocytes to bacteria or LPS evokes a signiﬁcant
increase in expression of monocyte PBP and derivatives
thereof [171]. This response involves activation of pro-
teinase-activated receptors (PARs) by thrombin or
synthetic peptide ligands such as SFLLRN. Importantly,
two bactericidal derivatives of PBP were seen to enter
phagolysosomes, ostensibly to act therein to aid in intra-
cellular inactivation and killing of pathogens. These
ﬁndings reinforce the prior discoveries that PBP and other
PMPs or kinocidins are multifunctional antimicrobial
effector proteins as discussed below.
Kinocidins integrate complementary antimicrobial
defense systems
Kinocidins orchestrate key events that provide innate anti-
infective defenses in settings of infection, and bridge
adaptive immunity as optimized to control speciﬁc
pathogens. Kinocidins have well-established chemotactic
functions known to recruit and activate antimicrobial
mechanisms of leukocytes and lymphocytes. Yeaman and
Yount have recently described how these molecules are
optimized to defend against infection of distinct physio-
logic and anatomic contexts, and in dynamic contexts, as
they change over time in response to infection [161, 163,
170]. This paradigm of immunocoordination is termed the
AEGIS model of host defense effector peptides: Arche-
type Effectors Governing Immune Syntax [157]. This
model derives from another recent advance in under-
standing host defense immunobiology—antimicrobial
peptide immunorelativity [157, 163]. This concept is a
functional concatenation of molecular regulation and
physicochemical optimization of host defense peptide
structures and functions in particular anatomic or physi-
ologic context to defend against cognate pathogens. Thus,
PMPs, kinocidins, and leukocytes recursively potentiate
one another in host defense against infection. The AEGIS
model of immunocoordination as applied to kinocidins is
exempliﬁed through an integration of multiple lines of
evidence.
Modular architecture
Kinocidins exhibit modular functional domains that can be
deployed to act autonomously to facilitate cooperative,
synergistic host defense functions. For example, kinocidins
effect immediate and direct antimicrobial actions, recruit
leukocytes to sites of infection, and potentiate the antimi-
crobial mechanisms of these cells [1, 6–9]. Excellent
studies by the Gallo laboratory [172] have also suggested
that certain human cathelicidins also encode multifunc-
tional capacity for host defense.
Immune syntax
The coordinated deployment of multiple and complemen-
tary defense mechanisms such as those encoded in
kinocidins in sequence, place, and time to optimize host
defense has been termed immune syntax. This process is
believed to occur through a corresponding series of events
[157]: (1) hallmark signals of infection evoke host cell
release of kinocidins in cognate physiologic, anatomic, and
microbiologic contexts in response to microbial signals or
tissue injury; (2) afﬁnity for microbial cells then concen-
trates native kinocidins, and their antimicrobial domains
begin to exert immediate antimicrobial activity; (3) prote-
olytic cleavage yields further diversity of functions,
including protease inhibition to extend peptide lifespan; (4)
diffusion of kinocidin chemotactic domains establishes
gradients for leukocyte chemonavigation, and potentiates
their antimicrobial mechanisms en route; (5) in turn, pre-
decoration by kinocidin opsonic domains promotes patho-
gen phagocytosis by recruited leukocytes, and in turn
potentiate leukocyte; and (6) in the restricted context of the
acidic phagolysosome, certain kinocidins or domains
thereof have enhanced microbicidal properties. Thus,
through immune syntax, kinocidins contribute to host
defense through coordinated deployment of direct and
indirect antimicrobial functions as optimized to context.
Molecular mechanisms of PMP and kinocidin response
Platelets can be viewed as vehicles, which sense molecular
signals of tissue infection or injury and respond by deliv-
ering anti-infective molecules and wound-healing factors.
Thus, the protective roles of PMPs and kinocidins rely on
platelet detection of warning signals, and prompt mobili-
zation and release of these molecules to act in innate host
defense. As detailed above, PMPs and kinocidins are
released from platelets upon exposure to infection-relevant
stimuli, such as thrombin, S. aureus a-toxin, or microbial
pathogens, including viridans group streptococci, S. aur-
eus, and C. albicans. Recent studies have provided new
insights into the molecular mechanisms through which
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pathogens. Trier et al. [173] demonstrated that platelets
release PMPs and kinocidins through speciﬁc molecular
pathways following interaction with S. aureus. At platelet–
S. aureus ratios of 10:1 or greater, platelet activation
occurred and resulted in release of staphylocidal levels
of PMPs and kinocidins. Apyrase (ADP degradation),
suramin (a general P2 receptor antagonist), pyridoxal
5-phosphonucleotide derivative (a speciﬁc P2X1 antago-
nist), and cangrelor (a speciﬁc P2Y12 antagonist) mitigated
the staphylocidal response against both strains, correlating
with reduced levels of PMP and PK release. Speciﬁc
inhibition occurred in the presence and absence of
homologous plasma. In contrast, inhibition of thromboxane
A2, COX-1 or -2, or phospholipase C pathways, or
hindrance of surface adhesion receptors, did not impede
anti-S. aureus responses. Taken together, this pattern of
data suggests a multifactorial platelet anti-S. aureus
response mechanism involving: (1) platelet activation in
response to S. aureus; (2) ensuing degranulation of
PMPs, kinocidins, and ADP/ATP; (3) ADP activation of
P2X1/P2Y12 receptors on adjacent platelets; and (4)
recursive ampliﬁcation of PMP and kinocidin release from
successive platelets. Thus, PMP and kinocidin response to
S. aureus occurs via an active, rapid and direct mechanism,
ampliﬁed through autocrine pathways in which platelet
ADP/ATP release prompts successive waves of platelet
degranulation via the platelet P2X and P2Y12 adenosine
nucleotide receptor array (Fig. 1). Sharma et al. showed
that outer membrane constituents of Porphyromonas
Fig. 1 Model of platelet interactions with Staphylococcus aureus.
Based upon recent evidence, the model illustrates how platelets may
sense and respond via parallel pathways that promote anti-staphylo-
coccal host defense. a On the cellular level, interactions with
S. aureus evoke: (1) platelet activation via speciﬁc receptors; (2)
liberation and processing of PMPs and PKs which exert direct
microbicidal effects, and (3) secretion of adenosine nucleotides
(ADP/ATP) triggering a recursive cascade for activation of adjacent
platelets. Note that inhibitors of the purinergic pathway of activation
preclude anti-staphylococcal responses. b On the molecular level,
speciﬁc sense and response pathway components are illustrated.
Purinergic agonists such as ADP are known stimulants of strong
platelet activation. Thus, degradation of extracellular ADP by apyrase
(APY) or the inhibition of P2X or P2Y12 adenosine nucleotide
receptors by suramin (SUR; general P2 inhibitor), pyridoxal-50-
phosphonucleotide derivative (PND; high-afﬁnity P2X1 inhibitor), or
cangrelor (CNG; high-afﬁnity P2Y12 inhibitor) speciﬁcally prevents
platelet (PLT) sense and response activation for staphylocidal
efﬁcacy. In contrast, antagonism of the P2Y1, phospholipase C
(PLC), thromboxane A2 (TXA2), or cyclooxygenase (COX) pathways,
or inhibition of the CD41, CD42b, or CD62P platelet adhesin
receptors do not impede the sense and response activation of platelets
versus S. aureus. Thus, the antistaphylococcal efﬁcacy of platelets
involves a self-amplifying, recursive sense and response mechanism:
(1) direct or indirect interactions of platelets and S. aureus (SA); (2)
platelet activation, via autocrine or intercrine P2X1 or P2Y12 receptor-
mediated signal transduction prompting granule mobilization; (3)
degranulation and liberation of ADP/ATP from d-granules; (4)
deployment of direct antimicrobial effector molecules (PMPs and
PKs) from a-granules; and (5) adenosine nucleotide-mediated
activation of adjacent platelets, with the ensuing ampliﬁcation of
antimicrobial responses. Such interactions are likely inﬂuenced by
platelet-to-S. aureus ratios. In this respect, staphylocidal efﬁcacy
appears to involve a threshold platelet ratio to generate and sustain an
intercrine platelet cascade required to achieve PMP/PK concentra-
tions for staphylocidal efﬁcacy. Adapted from [173]
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degranulation through similar pathways [174].
Antibacterial efﬁcacy of platelets, PMPs,
and kinocidins
The speciﬁc antimicrobial mechanisms of PMP and kino-
cidin actions against bacterial or other pathogens are
detailed in other publications (e.g., [1, 175]). In brief, these
peptides are rapidly microbicidal, with mechanisms that
are distinguishable from classical antimicrobial peptides.
For example, the staphylocidal mechanisms of PMPs and
kinocidins against S. aureus differ from those of human
defensin NP-1 (hNP-1) in several important respects:
involvement of membrane potential (Dw), permeabiliza-
tion, and bactericidal kinetics. Therefore, the following
discussion highlights the novel and relevant themes in
platelet, PMP, and kinocidin antibacterial response.
Efﬁcacy of PMPs and kinocidins in vitro
A substantial body of literature now exists demonstrating
that PMPs and kinocidins effect direct, rapid, and potent
efﬁcacy against many microbial pathogens in vitro. For
example, PMPs and kinocidins exert potent and synergistic
in vitro microbicidal activities against Bacillus subtilis,
S. aureus, S. epidermidis, E. coli, and other bacteria
including Pseudomonas species, as well as non-bacterial
pathogens [152–159]. The microbicidal effects of these
molecules are exerted in nanomolar to low micromolar
concentrations (1–5 lg/ml), and across physiological ran-
ges of pH (5.5–8.0). PMPs and kinocidins appear to act
synergistically with one another against microbial patho-
gens in vitro [152, 153]. Importantly, PMPs and kinocidins
have also been shown to interact with one another to effect
synergistic antimicrobial activity [152]. Thus, antimicro-
bial activities of PMPs and kinocidins observed in vitro and
ex vivo are relevant to conditions which exist in vivo.
Efﬁcacy of PMPs and kinocidins ex vivo
MultiplelinesofevidenceindicatethatPMPsandkinocidins
exertantimicrobial activities inrelevantsettings ofinfection
ex vivo. The host defense roles of platelets of PMPs and
kinocidins appear to be involved in limiting infection of
vascular biomatrices. Mercier et al. [176] found that platelet
activation by thrombin 30 min prior to bacterial inoculation
correlated with a signiﬁcant staphylocidal effect in an ex
vivo model of infective endocarditis. Inhibition of S. aureus
was greatest in simulated infective endocarditis vegetations
during the post-colonization and proliferation phases of
infection. Reinforcing this interpretation, synthetic mimet-
ics of platelet kinocidins exert signiﬁcantly greater
antimicrobial efﬁcacy in human blood and plasma ex vivo
than in artiﬁcial medium, even after 2 h incubation in the
biomatrices prior to inoculation of the target organisms
[165]. Mercier et al. [177] also demonstrated that PMPs and
kinocidins act in consort with conventional antibiotics to
limit the evolution of simulated human infective endocar-
ditis vegetations. In these studies, activated platelets alone,
or in combination with antibiotics, inhibited the prolifera-
tionofS.aureusinmodelﬂuidorsimulatedvegetationsover
the initial 4-h period (P\0.05 vs controls). Nafcillin regi-
mens were inhibitory beyond 4 h against ISP479C in both
model phases. Interestingly, introduction of activated
platelets inhibited glycopeptide-intermediate-susceptible
S. aureus (GISA) proliferation in vegetations, but not in the
chamber model ﬂuid. The combination of platelets plus
nafcillin or vancomycin signiﬁcantly inhibited proliferation
of the GISA strain in vegetations as compared to platelets or
antibiotics alone. However, platelets were not signiﬁcantly
effective with or without nafcillin or vancomycin against a
PMP-resistant strain of S. aureus.
Complementary data suggest that platelets protect
against endovascular infections such as infective endo-
carditis by modulating the responses of adjacent platelets.
For example, PMPs and kinocidins appear to modify
S. aureus-induced platelet aggregation in vitro [100].
Exposure to sublethal concentrations of PMPs reduces
the velocity and magnitude of platelet aggregation by
S. aureus [99, 178, 179]. It is not yet known whether
these peptides do so by modulating bacterium-to-platelet
binding, or through other mechanisms. Filler et al. [180]
have also demonstrated that platelets protect human
umbilical vein endothelial cells (HUVECs) from in vitro
injury due to C. albicans. In these studies,
51chromium-
release from HUVECs due to C. albicans was reduced by
45% in the presence of a platelet-to-fungus ratio of 20:1.
Moreover, HUVEC protection by platelets was associated
with a 37% reduction in germ tube length in C. albicans
after a 2-h exposure. Thus, it is conceivable that platelets
defend vascular endothelium from bacterial injury or
infection.
Efﬁcacy of PMPs and kinocidins in vivo
Evidence from a body of recent literature demonstrates that
platelets activate immediately and in high quantity in
response to pathogens, as well as by soluble mediators and
surface ligands expressed by infected host cells. As
detailed herein and in previous comprehensive reviews
[1, 6–10], platelets also contribute other key host defense
effector functions, including: generation of microbicidal
reactive oxygen species; facilitate complement ﬁxation on
microbes; internalization and clearance of pathogens from
the bloodstream; generate and release of cytokines and
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execute antibody-dependent cell cytotoxicity against
pathogens; and potentiation of antimicrobial mechanisms
of leukocytes [181].
Previous investigations have established that PMPs and
kinocidin levels in human plasma increase dramatically
(four to sixfold) in settings of microbial infection in vivo.
For example, the plasma levels of kinocidin PF4 increase
in bacterial septicemia [182], streptococcal nephritis [183],
and many other microbial infections. Similarly, Wilson et.
al. [184] demonstrated that endotoxin prompts a marked
increase in circulating levels of soluble CD62, an indicator
of platelet a-degranulation . Interestingly, unlike most
other markers of inﬂammation, plasma concentrations of
this biomarker progressively increased for up to 8 h after
endotoxin injection in human volunteers. Therefore, PMPs
and kinocidins are likely released immediately and over a
window of time from platelets in response to relevant
signals of inﬂammation and infection, as well as microor-
ganisms themselves.
Consistent with these perspectives, platelet transfusion
is now well established to have clear beneﬁcial effects in a
number of clinical situations, including infection and sep-
sis. It is known that sufﬁcient platelet quantity and quality
are important to homeostasis and host defense. For exam-
ple, inherited platelet disorders including Wiscott–Aldrich
Syndrome, May–Hegglin Anomaly, and Gray-Platelet
Syndrome, strongly correlate with morbidity and mortality
due to S. aureus and other infections [1, 4]. However, such
conditions often represent a convergence of multiple dis-
orders in cell-mediated immunity, making deﬁnition of
platelet-speciﬁc roles in host defense difﬁcult to interpret.
Nonetheless, evidence for the role of platelets in immune
defense against infection in humans comes from diseases
of platelet dysfunction as highlighted below. Thus, the
speciﬁc roles of platelets in host defense have been
investigated in vivo using complementary approaches. The
following discussion illustrates host defense roles of
platelets in light of broader themes and recent examples of
such clinical conditions.
Deﬁciencies in platelet quantity
It is now becoming clear from experimental as well as
human studies that a threshold platelet count is an impor-
tant determinant in the host defense repertoire against
infection. Sullam et al. [185] used an experimental animal
model to examine the role of platelets in defense against
infective endocarditis. Viridans streptococci were used to
induce endocarditis in animals with normal platelet counts,
as compared with animals in which thrombocytopenia was
conferred by platelet-speciﬁc antibody. Importantly, these
study groups had no differences in leukocyte quantity or
quality, or complement activity. Thrombocytopenic ani-
mals had signiﬁcantly higher streptococcal densities in
vegetation as compared with their counterparts with normal
platelet counts. Other reports by Dankert et al. [146, 147,
186] likewise emphasize the concept that platelets act in
host defense against infective endocarditis.
In humans, thrombocytopenia is now increasingly rec-
ognized as a signiﬁcant, independent correlate of morbidity
and mortality due to infection. For example, in oncological
conditions and cancer chemotherapy, thrombocytopenia is
an independent predictor of increased risk of morbidity and
mortality due to bacterial or fungal infection [187–191].
Even in the absence of neutropenia, thrombocytopenia is
positively correlated with incidence and severity of bac-
terial pneumonia in the elderly [188]. Similarly, Chang
et al. [189] recently demonstrated thrombocytopenia to be
an independent predictor of increased infection and related
morbidity in liver transplant recipients. In this group, 50%
of patients with platelet counts of B30 9 10
9/L presented
with infection within 30 days of transplantation, as com-
pared with only 17% of patients with nadir platelet counts
above this threshold. Likewise, Santolaya et al. [191] also
evaluated ﬁve potential factors for risk of invasive bacterial
infection: C-reactive protein serum level, hypotension,
leukemia relapse, thrombocytopenia (B50 9 10
9/L), or
chemotherapy. Thrombocytopenia was found to be an
independent risk factor for bacterial infection in 12% of
children in this cohort study (sensitivity, speciﬁcity, posi-
tive and negative predictive values of 92, 76, 82, and 90%,
respectively). In a similar investigation, Yoshida et al.
[192] employed multivariate analysis to ﬁnd that reduced
platelet count is an independent predictor of severe bac-
teremia in healthcare settings. Substantiating these data,
Mavrommatis et al. [193] distinguished platelet function
from overall coagulation responses to infection in humans.
In the initial state, uncomplicated sepsis correlates with
increases in blood levels of ﬁbrinopeptide-A, a PMP, and
the kinocidin PF4. Increased levels of such molecules were
temporally associated with a reduction in platelet count,
indicating clearance of activated upon degranulation.
However, platelet responsivity is often reduced as coagu-
lation factors are depleted in sepsis, as in other severe
infections.
Deﬁciencies in platelet activation
The above studies strongly suggest that a threshold platelet
count is an important barrier to infection. Beyond their
number, the ability of platelets to sense and respond to
soluble or cellular signals of infection appears to play a
signiﬁcant role in host defense. While platelets can sense
and respond to pathogens, key activators of platelets are
host signals emanating from injured or infected tissues. For
538 M. R. Yeamanexample, tissue infection often results in the elaboration of
tissue factor, which in turn activates the cleavage of
thrombin from pro-thrombin. In a recent investigation, Sun
et al. [194] reported that deﬁciencies in thrombin genera-
tion increase host susceptibility to group A streptococcal
infection. In these studies, mice made deﬁcient in factor V
(FV) either as circulating in plasma or contained in platelet
compartments, were challenged with group A streptococcal
infection. A reduction of FV in either pool was associated
with marked increases in infection-caused mortality, in
comparison to mice with normal levels of FV. Moreover,
ﬁbrinogen deﬁciency also yielded a signiﬁcant increase in
mortality to infection relative to controls. These ﬁndings
support the concept that constituents mediating platelet
signaling and response in local platelet activation and
thrombosis contribute to host defense against bacterial
pathogenesis.
Future perspectives
Immune system cells have evolved highly sophisticated
molecular and cellular systems with which to detect and
defend against infection. Platelets represent a highly
specialized member of this repertoire. Although these
cells have no nucleus, they retain unambiguous structural
and functional attributes of host defense effector cells.
Platelets are now known to express TLRs and many other
typical characteristics of innate immune effector cells that
play key and multifaceted roles in host defense against
infection. Evidence substantiating this role derives from
an integration of ﬁndings over the last decade, including:
(1) the discovery of PMPs and kinocidins released from
platelets; (2) experimental animal models in which
platelets signiﬁcantly contribute to host defense; and (3)
increased susceptibility to infection in clinical deﬁciencies
of platelet quantity or quality. Thus, platelets are sentinel
cells that can detect infection and deliver antimicrobial
effector molecules in innate defense and which potentiate
the efﬁcacy of leukocytes and other host defense systems.
In turn, bacterial pathogens have evolved myriad surface
proteins and other mechanisms by which to interact with
platelets. In some pathogens, adherence and activation of
platelets appear to subvert platelet responses and con-
tribute to virulence. These advances emphasize the
importance of future studies of human diseases and ani-
mal models to elucidate the roles of platelets in
prevention or limitation of infection. Moreover, studies of
speciﬁc platelet inhibitors may reveal important insights
into platelet function in human infections, and lead to new
anti-infective agents or strategies. For example, novel
anti-infectives designed upon PMPs and kinocidins have
already demonstrated efﬁcacy against antibiotic-resistant
pathogens in vivo. In addition, such molecules or immu-
nobiotics appear to amplify the efﬁcacy of conventional
antimicrobial agents, and therefore might be useful to
restore or enhance or efﬁcacies of conventional anti-
infective against resistant pathogens.
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